MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$2,676K
Free Cash flow
-$2,676K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Change in fair value - equity me...
Stock-based compensation
Change in fair value - senior se...
Others
Negative Cash Flow Breakdown
Net income (loss) - before nonco...
Change in fair value - rights li...
Purchase of equipment
Non-cash lease expense
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Change in fair value - equity method investment
-
-
-4,382
10,361
Gain on deconsolidation of subsidiary
-
-
0
-
Net income (loss) - before noncontrolling interest (nci)
-6,598
-1,352
-6,012
6,300
Depreciation and amortization expense
19
-67
22
65
Stock-based compensation
917
-1,293
383
1,092
Change in fair value - equity method investment
-2,504
1,878
-
-
Issuance of stock for services
0
1,951
-
-
Change in fair value - senior secured convertible notes
565
-3,360
-
-
Amortization of common stock payment for vendor service agreement
-
-
52
103
Change in fair value - warrant liability
0
-1,831
-
-
Change in fair value - senior secured convertible notes
-
-
100
249
Change in fair value - rights liability
24
30
-
-
Debt extinguishment loss - senior secured convertible note
0
-3,364
0
-58
Non-cash lease expense
-8
-17
5
6
Accounts receivable
-5
21
0
-15
Prepaid expenses, deposits and current and other assets
-
16
-345
259
Accounts payable
75
618
-47
-268
Accrued expenses and other current liabilities
369
-530
-116
253
Net cash flows used in operating activities
-2,663
1,035
-896
-2,759
Decrease in cash due to deconsolidation of subsidiary
-
-
0
-
Proceeds subsidiary common stock employee stock purchase plan
-
-
0
0
Proceeds from sale of intellectual property to lucid diagnostics inc
-
-
0
-
Proceeds exercise of stock options issued under equity plan of subsidiary
-
-
0
0
Purchase of equipment
13
5
3
14
Proceeds issue common stock employee stock purchase plan
-
-
0
0
Net cash flows used in investing activities
-13
-5
-3
-14
Proceeds issue of series d preferred stock, net of financing fees
0
29,910
0
0
Proceeds - senior secured convertible note (february 2026)
0
15,000
-
-
Payment - senior secured convertible note (september 2022)
0
11,149
0
0
Payment - series c preferred stock
0
26,197
-
-
Proceeds issue of common stock and pre-funded warrants, net of financing fees
0
-2,370
0
2,370
Proceeds issue of common stock - subsidiary, net of financing costs
-
-
-2
2,490
Proceeds issue of common stock - subsidiary
-841
-
0
841
Payment financing costs debt exchange
0
-109
0
109
Proceeds issue of common stock - subsidiary
0
0
-
-
Net cash flows provided by financing activities
0
1,974
-2
5,592
Net increase in cash
-2,676
3,004
-901
2,819
Cash, beginning of period
3,103
3,103
1,185
-
Cash, end of period
3,784
6,460
3,103
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net increase in cash
-$2,676K
(-194.93%↓ Y/Y)
Change in fair value -
equity method...
-$2,504K
(-124.17%↓ Y/Y)
Stock-based compensation
$917K
(-16.03%↓ Y/Y)
Change in fair value -
senior secured...
$565K
(126.91%↑ Y/Y)
Accrued expenses and
other current...
$369K
(45.85%↑ Y/Y)
Accounts payable
$75K
(127.99%↑ Y/Y)
Depreciation and
amortization expense
$19K
(-70.77%↓ Y/Y)
Accounts receivable
-$5K
(66.67%↑ Y/Y)
Net cash flows used
in operating...
-$2,663K
(3.48%↑ Y/Y)
Net cash flows used
in investing...
-$13K
(7.14%↑ Y/Y)
Canceled cashflow
$4,454K
Net income (loss) -
before noncontrolling...
-$6,598K
(-204.73%↓ Y/Y)
Purchase of equipment
$13K
(-7.14%↓ Y/Y)
something is missing
-$487K
Change in fair value -
rights liability
$24K
Non-cash lease expense
-$8K
(-233.33%↓ Y/Y)
Buy us a coffee
PAVmed Inc. (PAVM)
PAVmed Inc. (PAVM)